Urinary Tract Infections - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 117 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Urinary Tract Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Urinary Tract Infections - Pipeline Review, H2 2014', provides an overview of the Urinary Tract Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Urinary Tract Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Urinary Tract Infections Overview 9
Therapeutics Development 10
Pipeline Products for Urinary Tract Infections - Overview 10
Pipeline Products for Urinary Tract Infections - Comparative Analysis 11
Urinary Tract Infections - Therapeutics under Development by Companies 12
Urinary Tract Infections - Therapeutics under Investigation by Universities/Institutes 15
Urinary Tract Infections - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Urinary Tract Infections - Products under Development by Companies 19
Urinary Tract Infections - Products under Investigation by Universities/Institutes 20
Urinary Tract Infections - Companies Involved in Therapeutics Development 21
Shionogi & Co., Ltd. 21
AstraZeneca PLC 22
Merck & Co., Inc. 23
Melinta Therapeutics, Inc 24
Cubist Pharmaceuticals, Inc. 25
The Medicines Company 26
Paratek Pharmaceuticals, Inc. 27
Nymox Pharmaceutical Corporation 28
Achaogen Inc. 29
MerLion Pharmaceuticals Pte Ltd 30
GlycoVaxyn AG 31
Osel Inc. 32
Syntiron LLC 33
Nabriva Therapeutics AG 34
FOB Synthesis, Inc. 35
Sequoia Sciences, Inc. 36
Tetraphase Pharmaceuticals Inc. 37
Da Volterra 38
Adenium Biotech ApS 39
Urinary Tract Infections - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
(ceftolozane + tazobactam) - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
eravacycline - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
(RPX-2014 + RPX-7009) - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
plazomicin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
delafloxacin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
LACTIN-V - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
(ceftaroline + avibactam) - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
finafloxacin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
S-649266 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
relebactam - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
omadacycline tosylate - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Conjugate Vaccine for Extraintestinal Pathogenic E. Coli Infections - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
(biapenem + RPX-7009) - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Vaccine for Urinary Tract Infection - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
NXB-4221 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecule for Infectious Diseases - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
GP-4 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Micselon - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
cefepime - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Nu-3 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
DAV-210 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
AA-139 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
FSI-1686 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Inhibit 50S RNA for Infections - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Drugs to Inhibit COX-2 for Urinary Tract Infections - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Proteins for Infectious Diseases - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
escherichia coli vaccine - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
klebsiella pneumoniae vaccine - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
NXC-4720 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Urinary Tract Infections - Recent Pipeline Updates 89
Urinary Tract Infections - Dormant Projects 103
Urinary Tract Infections - Discontinued Products 104
Urinary Tract Infections - Product Development Milestones 105
Featured News & Press Releases 105
Jul 28, 2014: Tetraphase Pharmaceuticals Completes Enrollment of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections 105
Jul 01, 2014: GlycoVaxyn announces the initiation of a Phase I clinical trial in collaboration with Janssen for a vaccine against Extra-intestinal pathogenic Escherichia coli causing urinary tract infection 106
Jun 19, 2014: Cubist Announces Acceptance of Ceftolozane/Tazobactam New Drug Application with Priority Review 107
Jun 19, 2014: Tetraphase Pharmaceuticals Completes Enrollment in Lead-in Portion of IGNITE 2 Eravacycline Phase 3 Clinical Trial in cUTI 107
May 09, 2014: Cubist Presents Detailed Results from Positive Phase 3 Trials of Ceftolozane/Tazobactam at 2014 European Congress of Clinical Microbiology and Infectious Diseases 108
Apr 21, 2014: Cubist Announces Submission of New Drug Application for Investigational Antibiotic Ceftolozane/tazobactam 110
Apr 02, 2014: FDA Awards Fast Track Status to Tetraphase Pharmaceuticals for IV and Oral Formulations of Eravacycline 111
Mar 20, 2014: Tetraphase Pharmaceuticals Provides Update on Clinical Progress of Phase 3 Lead Antibiotic Candidate Eravacycline 112
Nov 25, 2013: Cubist Announces Positive Top-Line Results from Phase 3 Trial of Investigational Antibiotic Ceftolozane/Tazobactam In Complicated Urinary Tract Infections 113
Oct 02, 2013: Cubist To Present Data On Late Stage Candidates Ceftolozane/Tazobactam At IDWeek 2013 115
Appendix 116
Methodology 116
Coverage 116
Secondary Research 116
Primary Research 116
Expert Panel Validation 116
Contact Us 117
Disclaimer 117

List of Tables
Number of Products under Development for Urinary Tract Infections, H2 2014 10
Number of Products under Development for Urinary Tract Infections - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Development by Companies, H2 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Late Stage Development, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Investigation by Universities/Institutes, H2 2014 20
Urinary Tract Infections - Pipeline by Shionogi & Co., Ltd., H2 2014 21
Urinary Tract Infections - Pipeline by AstraZeneca PLC, H2 2014 22
Urinary Tract Infections - Pipeline by Merck & Co., Inc., H2 2014 23
Urinary Tract Infections - Pipeline by Melinta Therapeutics, Inc, H2 2014 24
Urinary Tract Infections - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 25
Urinary Tract Infections - Pipeline by The Medicines Company, H2 2014 26
Urinary Tract Infections - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 27
Urinary Tract Infections - Pipeline by Nymox Pharmaceutical Corporation, H2 2014 28
Urinary Tract Infections - Pipeline by Achaogen Inc., H2 2014 29
Urinary Tract Infections - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2014 30
Urinary Tract Infections - Pipeline by GlycoVaxyn AG, H2 2014 31
Urinary Tract Infections - Pipeline by Osel Inc., H2 2014 32
Urinary Tract Infections - Pipeline by Syntiron LLC, H2 2014 33
Urinary Tract Infections - Pipeline by Nabriva Therapeutics AG, H2 2014 34
Urinary Tract Infections - Pipeline by FOB Synthesis, Inc., H2 2014 35
Urinary Tract Infections - Pipeline by Sequoia Sciences, Inc., H2 2014 36
Urinary Tract Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014 37
Urinary Tract Infections - Pipeline by Da Volterra, H2 2014 38
Urinary Tract Infections - Pipeline by Adenium Biotech ApS, H2 2014 39
Assessment by Monotherapy Products, H2 2014 40
Assessment by Combination Products, H2 2014 41
Number of Products by Stage and Target, H2 2014 43
Number of Products by Stage and Mechanism of Action, H2 2014 45
Number of Products by Stage and Route of Administration, H2 2014 47
Number of Products by Stage and Molecule Type, H2 2014 49
Urinary Tract Infections Therapeutics - Recent Pipeline Updates, H2 2014 89
Urinary Tract Infections - Dormant Projects, H2 2014 103
Urinary Tract Infections - Discontinued Products, H2 2014 104